Chargement en cours...
Targeted α-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies
The approval of (223)Ra dichloride ((223)RaCl(2)) in 2013 was a principal event in introducing targeted α-therapy as a form of safe and effective management strategy in cancer. There is an increasing interest in research and development of new targeted α-therapy agents spearheaded by advancements in...
Enregistré dans:
| Publié dans: | Cancer Biother Radiopharm |
|---|---|
| Auteur principal: | |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Mary Ann Liebert, Inc., publishers
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7475102/ https://ncbi.nlm.nih.gov/pubmed/32202923 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/cbr.2019.3340 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|